Julia R. Brinton

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Movable Ink, an artificial intelligence-powered personalized content platform, on its definitive agreement to be acquired by STG. The transaction is expected to close in July 2025.

Cooley advised AIRO Group Holdings, a company specializing in advanced aerospace and defense technologies, on its $69 million initial public offering (IPO).

Cooley advised Kudu Dynamics, a company developing state-of-the-art cyber capabilities and nonkinetic effects against a variety of military-relevant systems, on its sale to Leidos (NYSE: LDOS), an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations.